Lenvatinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Stage III
Conditions
Unresectable Stage III, Stage IV Melanoma
Trial Timeline
Aug 1, 2010 → Nov 1, 2014
NCT ID
NCT01136967About Lenvatinib
Lenvatinib is a phase 2 stage product being developed by Eisai for Unresectable Stage III. The current trial status is completed. This product is registered under clinical trial identifier NCT01136967. Target conditions include Unresectable Stage III, Stage IV Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Unresectable Stage III